Page 1

illumina Second quarter results reflect record revenue : ● Investors : Brian Blanchett +1.858.291.6421 ir@illumina.com San Diego -- ( PRNewswire ) - August 5 , 2021 - Illumina , Inc. ( NASDAQ : ILMN ) today announced its financial results for the second quarter of fiscal year 2021 . ● Media : Dr. Karen Birmingham +1.646.355.2111 kbirmingham@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021 Raises Fiscal Year 2021 Guidance Revenue of $ 1,126 million , a 78 % increase compared to the prior year period GAAP net income for the quarter of $ 185 million , or $ 1.26 per diluted share , compared to $ 47 million , or $ 0.32 per diluted share , for the prior year period Non - GAAP net income for the quarter of $ 276 million , or $ 1.87 per diluted share , compared to $ 92 million , or $ 0.62 per diluted share , for the prior year period . Non - GAAP net income excludes acquisition - related expenses , primarily the Continuation Payments paid to GRAIL ( see the " Reconciliation Between GAAP and Non - GAAP Net Income " table for a reconciliation of these GAAP and non - GAAP financial measures ) Cash flow from operations of $ 253 million compared to $ 240 million in the prior year period Free cash flow ( cash flow from operations less capital expenditures ) of $ 209 million for the quarter compared to $ 202 million in the prior year period " Illumina's record second quarter revenue exceeded expectations across all regions , " said Francis deSouza , Chief Executive Officer . " This demonstrates the strength of our business led by clinical applications , including oncology and genetic disease testing , as well as research . Additionally , we are proud of the critical role that NGS plays in identifying and monitoring COVID - 19 variants to inform strategies to combat the pandemic . As a result of the enduring strength of the core business , we are again raising our 2021 financial guidance . " Gross margin in the second quarter of 2021 was 71.2 % compared to 67.7 % in the prior year period . Excluding amortization of acquired intangible assets , non - GAAP gross margin was 71.8 % for the second quarter of 2021 compared to 68.6 % in the prior year period . Research and development ( R & D ) expenses for the second quarter of 2021 were $ 202 million compared to $ 155 million in the prior year period . Non - GAAP R & D expenses as a percentage of revenue were 18.0 % compared to 24.7 % in the prior year period . Selling , general and administrative ( SG & A ) expenses for the second quarter of 2021 were $ 413 million compared to $ 177 million in the prior year period . Excluding acquisition - related expenses , gain on litigation , and expenses related to COVID - 19 , non - GAAP SG & A expenses as a percentage of revenue were 23.8 % compared to 28.1 % in the prior year period .